Key Highlights

  • Second-quarter Revenue at Formula Systems rose 29.8% to USD 782.4 million, but its November 19, 2026 third-quarter date is unconfirmed, and last year's report arrived November 20, 2025.
  • Arbe Robotics needs roughly USD 2.8 million of second-half revenue to reach the bottom of its USD 4 million through 6 million guide (calculated), after about USD 1.2 million in the first half.
  • Cash at Evogene was USD 9.3 million on June 30, 2026, and management guides 2026 cash usage to USD 8.5 million through USD 9.5 million, versus roughly USD 14.4 million used in 2025.
  • On October 28, 2026 Endava withdrew earlier guidance and said a restatement may cut revenue by about 2% to 4% of the fiscal 2025 figure, which puts the November 19 slot in question.

Formula Systems (NASDAQ:FORTY): Restated-Base Growth and an Unverified Date

Formula Systems (NASDAQ:FORTY) appears on an Earnings calendar for November 19, 2026, covering third-quarter 2026, with no time shown, and the company has posted no notice of that date. No EPS estimate appears on the calendar, and no published EPS or revenue consensus turned up for Formula Systems (NASDAQ:FORTY). In the second quarter, revenue climbed 29.8% to USD 782.4 million and Operating Income gained 41.3% to USD 71.6 million, while diluted EPS of USD 1.47 compares with USD 0.95 on a restated base, since Sapiens counts as discontinued after the December 2025 sale. Nobody verified a consensus for the period, so no beat or miss is stated, and there is no formal guidance. Matrix IT, held at 47.68%, is the metric to watch at Formula Systems (NASDAQ:FORTY), with revenue up only 6.3% in shekel terms. Currency translation and restatement effects that can distort growth comparisons are the risk at Formula Systems (NASDAQ:FORTY). Holders of Formula Systems (NASDAQ:FORTY) should read growth carefully.

Alpha Tau Medical (NASDAQ:DRTS): Tolmar Money and Trial Readouts Ahead of an Open Date

A calendar has Alpha Tau Medical (NASDAQ:DRTS) on November 19, 2026, and a second has it on November 26, so without a company notice the date is unconfirmed. The Israeli device developer shows an unverified calendar loss estimate of USD 0.15 per share and no published revenue consensus for Alpha Tau Medical (NASDAQ:DRTS). Its last report lacks a verified consensus comparison, and non-cash Warrant charges inflated the first-half net loss of USD 68.8 million. Progress toward readouts expected late in 2026, for pancreatic, glioblastoma and skin cancer studies, and toward the first US prostate patient, is the metric to watch. Funding from the Tolmar collaboration gives Alpha Tau Medical (NASDAQ:DRTS) USD 20 million of Equity and USD 15 million for a production facility, with milestones reaching USD 96.5 million for the first indication. Risk comes from a timeline slip at Alpha Tau Medical (NASDAQ:DRTS), likely to be read as a miss, or from higher research spending, which was USD 20.9 million in the first half. Investors in Alpha Tau Medical (NASDAQ:DRTS) should expect warrant noise.

Evogene (NASDAQ:EVGN): A USD 0.19 Loss Estimate and a Thin Cash Cushion

Third-quarter results from Evogene (NASDAQ:EVGN) are set for Thursday, November 19, 2026, with a management call that day, and one preview page calls the release pre-open. That page shows a single-source consensus loss of USD 0.19 per share on about USD 370,000 of revenue, and the calendar agrees on the loss figure. Second-quarter revenue dropped from USD 534,000 to USD 347,000 while the loss shrank to USD 1.8 million, equal to USD 0.14 per share, thanks partly to warrant Revaluation at Evogene (NASDAQ:EVGN). A consensus for that quarter was not found, which rules out a stated beat or miss for Evogene (NASDAQ:EVGN). Cash usage against the guide of USD 8.5 million through USD 9.5 million is the metric to watch for Evogene (NASDAQ:EVGN). The specific risk is a Nasdaq minimum bid price issue, with another 180 days granted according to the company. A few trades can move the price at this scale, spreads can be wide, and quoted moves at Evogene (NASDAQ:EVGN) can reverse. Funding is the other risk for Evogene.

Arbe Robotics (NASDAQ:ARBE): A Sales Gap and a Bond Proposal Ahead of the Open

Third-quarter 2026 results are confirmed by Arbe Robotics (NASDAQ:ARBE) for November 19, 2026, ahead of the U.S. open, with a conference call and live webcast. The radar chip maker trades on Nasdaq and the Tel Aviv Stock Exchange. The negative USD 0.06 EPS estimate on the calendar is unverified, and no consensus was found. Second-quarter revenue of USD 0.7 million, up from USD 0.3 million, came with a USD 9.1 million net loss, or USD 0.07 per share, and management at Arbe Robotics (NASDAQ:ARBE) reaffirmed its 2026 revenue guidance of USD 4 million through USD 6 million. The metric to watch is third-quarter revenue relative to the roughly USD 2.8 million still needed for the bottom of the guide, calculated from a single-source first-half figure. Slow automaker decisions are the risk, along with a proposed bond extension needing bondholder approval at Arbe Robotics (NASDAQ:ARBE). Cash and short-term deposits came to USD 41.9 million at June 30, 2026, and the small market cap of Arbe Robotics (NASDAQ:ARBE) can magnify price moves. Holders of Arbe Robotics (NASDAQ:ARBE) should watch the revenue gap.

Endava (NYSE:DAVA): Pulled Guidance and a Restatement Put the Date in Doubt

One calendar has Endava (NYSE:DAVA) reporting fiscal fourth-quarter results after the close on November 19, 2026, yet the company warned on October 28, 2026 that the November 2 Annual Report deadline would be missed and timing announced later. No new date turned up. Earlier fourth-quarter guidance of GBP 181 million through GBP 185 million of revenue was withdrawn, and the calendar's 0.1 EPS goes unused. Against a single-source consensus of GBP 183.87 million, third-quarter revenue of GBP 178.5 million fell short, while adjusted EPS of GBP 0.05 beat GBP 0.02, and both periods now face restatement at Endava (NYSE:DAVA). How large the restatement is, with cash near GBP 55 million, is the metric to watch for Endava (NYSE:DAVA). Risks include covenant compliance on the revolving Credit facility, findings of material weakness and interim leadership. Holders of Endava (NYSE:DAVA) face real uncertainty. The NYSE listing comes from a published headline, not a filing.

Where Things Stand

It depends, since none of the five has reported and two dates are unconfirmed. At Formula Systems (NASDAQ:FORTY), the 29.8% growth rests on a restated base with no guidance to measure it against. Partner funding but an open date describe Alpha Tau Medical (NASDAQ:DRTS). Cash is the story at micro-cap Evogene (NASDAQ:EVGN). Guidance is the story at similar-scale Arbe Robotics (NASDAQ:ARBE). The most uncertain is Endava (NYSE:DAVA), where a restatement could change the figures and may delay a report. The cases rest on different facts, so none should be read across, and consensus is thin or from a single source throughout.